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Introduction 
Cystic Fibrosis (CF) is a genetic disease which affects the body’s ability to regulate chloride movement 
across epithelial cells, leading to life-limiting conditions such as chronic airway infection and pancreatic
disease. Treatments for CF are emerging which aim to correct and enhance the underlying CFTR protein
dysfunction which causes the disease. Sweat Cl- concentration is a key biomarker in gauging the efficacy of
such treatments. To be able to measure Cl- in sweat non-invasively in real time, we are developing a
wearable, chloride-sensitive patch.
Methods 
Pre-manufactured Ag/AgCl electrodes printed on a flexible polyethylene substrate were utilised for this study,
consisting of a reference and working electrode. One of the electrodes was modified through the deposition
of a pHEMA hydrogel film over the surface. The hydrogel was polymerised under a UV LED array and
treated in a Cl- saturated solution to produce a stable Cl- reference electrode.
The device’s sensitivity towards Cl- ions was initially tested by observing the open circuit potential (OCP)
developed between the pHEMA reference electrode and Ag/AgCl working electrode when exposed to KCl
solutions of concentrations ranging from 1mM to 1M. This encompasses healthy physiological chloride
concentrations and those seen in CF patients.
In vitro studies have also been conducted using a fluid-filled cell with a nano-porous membrane surface,
designed to mimic the transdermal diffusion of ions.
       Figure 1. Experimental setup for in vitro skin model tests
Results & Discussion 
An average sensitivity of 54 mV per decade (n=4) was found, indicating that the electrodes display a near-
Nernstian response to the test solution concentration range. Tests undertaken with the in vitro skin model
system have also shown that the device is sensitive to changes in chloride concentration made to the filling
solution throughout the test period. These results indicate that the device is not only approaching the
physical limit of sensitivity toward Cl- concentrations within aqueous solutions, but that it has the capability of
monitoring Cl- levels via the diffusion of ions across a skin-like membrane.
Conclusion 
This study shows that pHEMA-adapted electrodes can be used to successfully detect clinically relevant
changes in Cl- concentration. Studies carried out with an in vitro cell suggest that the electrodes could be
used as part of a wearable device capable of monitoring transdermal chloride concentrations. Such a device
would play a vital role in monitoring the impact emerging CF treatments have on CFTR functionality, the
underlying cause of CF.
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